Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and effectiveness of using
durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor
receptor 2 (HER2)-enriched breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute